Andrea Steck
Concepts (305)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 1 | 103 | 2024 | 3245 | 8.860 |
Why?
| Autoantibodies | 64 | 2024 | 1354 | 7.070 |
Why?
| Islets of Langerhans | 37 | 2023 | 729 | 4.350 |
Why?
| Autoimmunity | 33 | 2022 | 818 | 3.000 |
Why?
| C-Peptide | 12 | 2022 | 138 | 2.680 |
Why?
| Insulin Antibodies | 11 | 2022 | 102 | 2.540 |
Why?
| Genetic Predisposition to Disease | 32 | 2022 | 2108 | 2.090 |
Why?
| Polymorphism, Single Nucleotide | 23 | 2021 | 1901 | 1.900 |
Why?
| Blood Glucose | 13 | 2023 | 1821 | 1.800 |
Why?
| Glutamate Decarboxylase | 17 | 2022 | 160 | 1.790 |
Why?
| Insulin | 21 | 2023 | 2082 | 1.650 |
Why?
| Disease Progression | 33 | 2022 | 2389 | 1.600 |
Why?
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 7 | 2019 | 46 | 1.460 |
Why?
| HLA-DR Antigens | 8 | 2016 | 220 | 1.370 |
Why?
| Child, Preschool | 54 | 2023 | 9093 | 1.360 |
Why?
| Child | 74 | 2023 | 18407 | 1.350 |
Why?
| Genotype | 22 | 2020 | 1780 | 1.170 |
Why?
| Adolescent | 54 | 2023 | 17864 | 1.050 |
Why?
| HLA-DQ Antigens | 8 | 2019 | 177 | 1.030 |
Why?
| Infant | 34 | 2023 | 7946 | 0.980 |
Why?
| HLA-DR3 Antigen | 8 | 2022 | 79 | 0.970 |
Why?
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 5 | 2017 | 58 | 0.940 |
Why?
| Diabetes Mellitus, Type 2 | 10 | 2022 | 2098 | 0.920 |
Why?
| Adaptor Proteins, Signal Transducing | 4 | 2017 | 370 | 0.910 |
Why?
| Insulin-Secreting Cells | 11 | 2021 | 318 | 0.900 |
Why?
| Blood Glucose Self-Monitoring | 6 | 2023 | 497 | 0.890 |
Why?
| Male | 74 | 2023 | 55731 | 0.840 |
Why?
| Humans | 113 | 2024 | 115042 | 0.820 |
Why?
| Female | 74 | 2023 | 59613 | 0.800 |
Why?
| Zinc Transporter 8 | 7 | 2021 | 86 | 0.800 |
Why?
| Haplotypes | 8 | 2022 | 455 | 0.780 |
Why?
| Mass Screening | 10 | 2022 | 1012 | 0.760 |
Why?
| Hyperglycemia | 2 | 2015 | 293 | 0.750 |
Why?
| Age of Onset | 12 | 2021 | 449 | 0.740 |
Why?
| HLA-D Antigens | 2 | 2019 | 34 | 0.740 |
Why?
| Prediabetic State | 4 | 2023 | 224 | 0.720 |
Why?
| Young Adult | 29 | 2022 | 10498 | 0.710 |
Why?
| Prospective Studies | 20 | 2024 | 6232 | 0.670 |
Why?
| HLA Antigens | 5 | 2022 | 224 | 0.660 |
Why?
| Genetic Testing | 6 | 2019 | 380 | 0.650 |
Why?
| Glucose Tolerance Test | 8 | 2023 | 344 | 0.650 |
Why?
| C-Reactive Protein | 2 | 2018 | 363 | 0.640 |
Why?
| Risk Factors | 28 | 2024 | 8642 | 0.630 |
Why?
| Hypoglycemic Agents | 5 | 2020 | 1006 | 0.620 |
Why?
| Family | 4 | 2018 | 591 | 0.600 |
Why?
| Diagnostic Techniques, Endocrine | 1 | 2017 | 14 | 0.590 |
Why?
| Celiac Disease | 4 | 2022 | 264 | 0.560 |
Why?
| Sensitivity and Specificity | 9 | 2022 | 1715 | 0.540 |
Why?
| Case-Control Studies | 12 | 2021 | 3015 | 0.510 |
Why?
| HLA-DR4 Antigen | 5 | 2022 | 76 | 0.470 |
Why?
| Models, Genetic | 1 | 2017 | 566 | 0.470 |
Why?
| Proinsulin | 2 | 2020 | 49 | 0.470 |
Why?
| Polymorphism, Genetic | 5 | 2019 | 617 | 0.430 |
Why?
| Follow-Up Studies | 10 | 2021 | 4420 | 0.430 |
Why?
| Quality Improvement | 2 | 2017 | 953 | 0.420 |
Why?
| Luminescence | 4 | 2016 | 34 | 0.420 |
Why?
| Transcription Factor 7-Like 2 Protein | 5 | 2021 | 24 | 0.420 |
Why?
| HLA-DQ beta-Chains | 4 | 2019 | 59 | 0.420 |
Why?
| Luminescent Measurements | 4 | 2021 | 74 | 0.410 |
Why?
| Cation Transport Proteins | 4 | 2017 | 123 | 0.400 |
Why?
| Adult | 26 | 2022 | 30656 | 0.370 |
Why?
| DNA Methylation | 4 | 2020 | 496 | 0.350 |
Why?
| Risk | 6 | 2019 | 815 | 0.330 |
Why?
| Twins, Monozygotic | 4 | 2018 | 210 | 0.330 |
Why?
| Antigens, CD | 2 | 2009 | 441 | 0.320 |
Why?
| HLA-DQ alpha-Chains | 3 | 2019 | 14 | 0.320 |
Why?
| Cohort Studies | 11 | 2021 | 4904 | 0.320 |
Why?
| Family Health | 4 | 2017 | 194 | 0.310 |
Why?
| HLA-DRB1 Chains | 3 | 2019 | 98 | 0.310 |
Why?
| Predictive Value of Tests | 6 | 2019 | 1812 | 0.300 |
Why?
| Transglutaminases | 2 | 2021 | 142 | 0.300 |
Why?
| Major Histocompatibility Complex | 4 | 2017 | 219 | 0.290 |
Why?
| Longitudinal Studies | 6 | 2020 | 2389 | 0.290 |
Why?
| Pancreas | 3 | 2024 | 280 | 0.290 |
Why?
| Risk Assessment | 5 | 2020 | 2976 | 0.280 |
Why?
| CTLA-4 Antigen | 3 | 2017 | 78 | 0.280 |
Why?
| Alleles | 4 | 2021 | 792 | 0.280 |
Why?
| Age Factors | 6 | 2022 | 2894 | 0.270 |
Why?
| Autoimmune Diseases | 3 | 2017 | 394 | 0.270 |
Why?
| Protein Tyrosine Phosphatases | 1 | 2006 | 147 | 0.260 |
Why?
| Autoantigens | 2 | 2021 | 397 | 0.250 |
Why?
| Prognosis | 6 | 2021 | 3334 | 0.250 |
Why?
| Diabetes Complications | 2 | 2018 | 212 | 0.250 |
Why?
| Biomarkers | 5 | 2021 | 3419 | 0.220 |
Why?
| Hydroxychloroquine | 1 | 2023 | 55 | 0.220 |
Why?
| Gene Frequency | 6 | 2020 | 483 | 0.220 |
Why?
| Proportional Hazards Models | 4 | 2021 | 1080 | 0.220 |
Why?
| Infant, Newborn | 7 | 2022 | 5040 | 0.210 |
Why?
| Diabetic Ketoacidosis | 2 | 2022 | 159 | 0.210 |
Why?
| Glucokinase | 2 | 2013 | 13 | 0.210 |
Why?
| Radioimmunoassay | 3 | 2017 | 163 | 0.200 |
Why?
| Chromosome Mapping | 2 | 2021 | 490 | 0.190 |
Why?
| Early Diagnosis | 3 | 2020 | 218 | 0.190 |
Why?
| Seroconversion | 1 | 2021 | 46 | 0.180 |
Why?
| Area Under Curve | 2 | 2020 | 275 | 0.180 |
Why?
| Benchmarking | 1 | 2022 | 161 | 0.180 |
Why?
| Colorado | 5 | 2023 | 4089 | 0.180 |
Why?
| Twins, Dizygotic | 2 | 2018 | 182 | 0.180 |
Why?
| GTP-Binding Proteins | 1 | 2021 | 141 | 0.180 |
Why?
| Precision Medicine | 1 | 2023 | 340 | 0.170 |
Why?
| Iodide Peroxidase | 2 | 2020 | 27 | 0.170 |
Why?
| Phospholipids | 1 | 2021 | 199 | 0.170 |
Why?
| Incidence | 4 | 2022 | 2318 | 0.160 |
Why?
| Receptors, Antigen, T-Cell | 2 | 2022 | 618 | 0.160 |
Why?
| Insulin Resistance | 3 | 2021 | 1077 | 0.160 |
Why?
| Down-Regulation | 1 | 2021 | 599 | 0.160 |
Why?
| Genome-Wide Association Study | 3 | 2019 | 1203 | 0.160 |
Why?
| Diabetes Mellitus | 2 | 2023 | 906 | 0.150 |
Why?
| Kaplan-Meier Estimate | 2 | 2017 | 814 | 0.150 |
Why?
| ROC Curve | 1 | 2019 | 447 | 0.150 |
Why?
| Middle Aged | 10 | 2022 | 26827 | 0.150 |
Why?
| Multivariate Analysis | 2 | 2016 | 1435 | 0.150 |
Why?
| Fasting | 2 | 2018 | 242 | 0.150 |
Why?
| Receptors, CCR7 | 1 | 2017 | 24 | 0.150 |
Why?
| Genetic Heterogeneity | 1 | 2017 | 49 | 0.150 |
Why?
| Discriminant Analysis | 1 | 2017 | 38 | 0.150 |
Why?
| Interferon-gamma | 1 | 2021 | 723 | 0.150 |
Why?
| Blood Specimen Collection | 1 | 2017 | 32 | 0.140 |
Why?
| Transcription Factors | 2 | 2017 | 1531 | 0.140 |
Why?
| Influenza, Human | 1 | 2022 | 546 | 0.140 |
Why?
| Health Care Costs | 1 | 2020 | 381 | 0.140 |
Why?
| Disease Management | 1 | 2020 | 563 | 0.140 |
Why?
| Genomics | 1 | 2021 | 641 | 0.140 |
Why?
| Genetic Variation | 1 | 2021 | 876 | 0.130 |
Why?
| Antibody Affinity | 1 | 2016 | 52 | 0.130 |
Why?
| Hypoglycemia | 2 | 2020 | 385 | 0.130 |
Why?
| Disease-Free Survival | 1 | 2017 | 617 | 0.130 |
Why?
| Peptides | 1 | 2021 | 849 | 0.130 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2020 | 1138 | 0.130 |
Why?
| Iron-Binding Proteins | 1 | 2015 | 38 | 0.120 |
Why?
| RNA, Long Noncoding | 1 | 2017 | 155 | 0.120 |
Why?
| Dried Blood Spot Testing | 1 | 2015 | 72 | 0.120 |
Why?
| Trans-Activators | 1 | 2017 | 368 | 0.120 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2017 | 386 | 0.120 |
Why?
| Repressor Proteins | 1 | 2017 | 368 | 0.120 |
Why?
| Antibodies, Monoclonal | 1 | 2020 | 1268 | 0.120 |
Why?
| Self Care | 1 | 2017 | 351 | 0.120 |
Why?
| Magnetic Resonance Imaging | 2 | 2024 | 3118 | 0.110 |
Why?
| Population Surveillance | 1 | 2017 | 392 | 0.110 |
Why?
| Glucose | 3 | 2023 | 900 | 0.110 |
Why?
| Hepatocyte Nuclear Factor 4 | 1 | 2013 | 13 | 0.110 |
Why?
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2013 | 16 | 0.110 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2018 | 691 | 0.110 |
Why?
| Genetic Linkage | 2 | 2011 | 297 | 0.110 |
Why?
| Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2012 | 11 | 0.100 |
Why?
| Chromosomes, Human, Pair 2 | 2 | 2009 | 27 | 0.100 |
Why?
| Receptors, Calcitriol | 1 | 2012 | 53 | 0.100 |
Why?
| United Kingdom | 3 | 2018 | 227 | 0.100 |
Why?
| Polymerase Chain Reaction | 1 | 2014 | 999 | 0.100 |
Why?
| Proteins | 1 | 2017 | 915 | 0.100 |
Why?
| Promoter Regions, Genetic | 1 | 2016 | 1133 | 0.100 |
Why?
| Genetic Association Studies | 3 | 2020 | 344 | 0.090 |
Why?
| Penetrance | 1 | 2011 | 27 | 0.090 |
Why?
| Siblings | 2 | 2018 | 224 | 0.090 |
Why?
| Dose-Response Relationship, Drug | 1 | 2015 | 1857 | 0.090 |
Why?
| Inflammation | 2 | 2020 | 2485 | 0.090 |
Why?
| DNA-Binding Proteins | 1 | 2017 | 1318 | 0.090 |
Why?
| Seroepidemiologic Studies | 2 | 2023 | 138 | 0.090 |
Why?
| Gene Expression | 2 | 2021 | 1423 | 0.090 |
Why?
| Vitamin D | 1 | 2013 | 340 | 0.090 |
Why?
| Glycopeptides | 1 | 2010 | 43 | 0.090 |
Why?
| Obesity | 2 | 2019 | 2524 | 0.090 |
Why?
| Genetic Markers | 1 | 2011 | 323 | 0.090 |
Why?
| Histocompatibility Antigens Class I | 1 | 2011 | 174 | 0.080 |
Why?
| Histocompatibility Antigens Class II | 1 | 2011 | 353 | 0.080 |
Why?
| Nuclear Family | 1 | 2009 | 49 | 0.080 |
Why?
| TCF Transcription Factors | 1 | 2008 | 20 | 0.080 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 744 | 0.080 |
Why?
| Asymptomatic Diseases | 2 | 2021 | 75 | 0.080 |
Why?
| Phenotype | 2 | 2017 | 2815 | 0.080 |
Why?
| DEAD-box RNA Helicases | 1 | 2008 | 56 | 0.080 |
Why?
| Mutation | 2 | 2015 | 3350 | 0.070 |
Why?
| Hospitalization | 1 | 2016 | 1754 | 0.070 |
Why?
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2006 | 44 | 0.070 |
Why?
| Gene-Environment Interaction | 2 | 2020 | 185 | 0.070 |
Why?
| Biosensing Techniques | 1 | 2007 | 99 | 0.070 |
Why?
| CpG Islands | 2 | 2016 | 118 | 0.070 |
Why?
| Leukocytes, Mononuclear | 1 | 2008 | 496 | 0.070 |
Why?
| Receptors, Interleukin-4 | 1 | 2005 | 15 | 0.060 |
Why?
| Cell Death | 2 | 2019 | 324 | 0.060 |
Why?
| Animals | 4 | 2022 | 31867 | 0.060 |
Why?
| Antigens, Differentiation | 1 | 2005 | 79 | 0.060 |
Why?
| Sex Characteristics | 1 | 2010 | 635 | 0.060 |
Why?
| CD4-Positive T-Lymphocytes | 2 | 2021 | 965 | 0.060 |
Why?
| Environment | 2 | 2018 | 335 | 0.060 |
Why?
| Interleukin-13 | 1 | 2005 | 123 | 0.060 |
Why?
| Drug Delivery Systems | 1 | 2007 | 296 | 0.060 |
Why?
| Fathers | 1 | 2005 | 45 | 0.060 |
Why?
| Interleukin-4 | 1 | 2005 | 209 | 0.060 |
Why?
| Europe | 2 | 2015 | 336 | 0.060 |
Why?
| Feasibility Studies | 2 | 2017 | 746 | 0.050 |
Why?
| Parents | 2 | 2023 | 1190 | 0.050 |
Why?
| Practice Guidelines as Topic | 2 | 2023 | 1398 | 0.050 |
Why?
| Prevalence | 2 | 2023 | 2255 | 0.050 |
Why?
| Time Factors | 3 | 2018 | 6141 | 0.050 |
Why?
| Stroke | 1 | 2010 | 1015 | 0.050 |
Why?
| Electrochemistry | 1 | 2021 | 78 | 0.050 |
Why?
| Reproducibility of Results | 2 | 2021 | 2799 | 0.050 |
Why?
| China | 1 | 2021 | 163 | 0.050 |
Why?
| Perception | 1 | 2023 | 310 | 0.050 |
Why?
| Consensus | 1 | 2023 | 534 | 0.050 |
Why?
| Diagnostic Techniques, Radioisotope | 1 | 2021 | 8 | 0.050 |
Why?
| Immunoglobulin D | 1 | 2021 | 27 | 0.050 |
Why?
| Diffusion Magnetic Resonance Imaging | 1 | 2021 | 85 | 0.050 |
Why?
| Sequence Analysis, DNA | 2 | 2016 | 728 | 0.050 |
Why?
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2022 | 309 | 0.050 |
Why?
| Serologic Tests | 1 | 2021 | 49 | 0.050 |
Why?
| Latent Autoimmune Diabetes in Adults | 1 | 2020 | 2 | 0.050 |
Why?
| Phantoms, Imaging | 1 | 2021 | 137 | 0.050 |
Why?
| Protein Interaction Mapping | 1 | 2021 | 102 | 0.050 |
Why?
| Healthy Volunteers | 1 | 2021 | 197 | 0.050 |
Why?
| Electrochemical Techniques | 1 | 2021 | 45 | 0.040 |
Why?
| Aged | 3 | 2021 | 19119 | 0.040 |
Why?
| Drug Discovery | 1 | 2021 | 124 | 0.040 |
Why?
| Whole Genome Sequencing | 1 | 2020 | 96 | 0.040 |
Why?
| Glutens | 1 | 2020 | 56 | 0.040 |
Why?
| Peroxidase | 1 | 2020 | 157 | 0.040 |
Why?
| Mannose | 1 | 2019 | 21 | 0.040 |
Why?
| Quality-Adjusted Life Years | 1 | 2020 | 101 | 0.040 |
Why?
| Linkage Disequilibrium | 2 | 2011 | 245 | 0.040 |
Why?
| Immunoglobulin A | 1 | 2021 | 171 | 0.040 |
Why?
| Adenosine Diphosphate | 1 | 2019 | 81 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 441 | 0.040 |
Why?
| Immunoglobulin M | 1 | 2021 | 251 | 0.040 |
Why?
| Evidence-Based Medicine | 1 | 2023 | 676 | 0.040 |
Why?
| Antibodies, Viral | 1 | 2023 | 522 | 0.040 |
Why?
| Costs and Cost Analysis | 1 | 2020 | 196 | 0.040 |
Why?
| Immunoglobulin E | 1 | 2021 | 323 | 0.040 |
Why?
| Butyrates | 1 | 2019 | 53 | 0.040 |
Why?
| Mothers | 1 | 2005 | 652 | 0.040 |
Why?
| Ascorbic Acid | 1 | 2019 | 110 | 0.040 |
Why?
| Infant, Newborn, Diseases | 1 | 2020 | 104 | 0.040 |
Why?
| Methylation | 1 | 2019 | 208 | 0.040 |
Why?
| Fibrinogen | 1 | 2019 | 155 | 0.040 |
Why?
| Molecular Targeted Therapy | 1 | 2021 | 347 | 0.040 |
Why?
| Emotional Adjustment | 1 | 2018 | 17 | 0.040 |
Why?
| Antibody Specificity | 1 | 2018 | 176 | 0.040 |
Why?
| Interleukins | 1 | 2020 | 236 | 0.040 |
Why?
| Sweden | 1 | 2018 | 65 | 0.040 |
Why?
| Pennsylvania | 1 | 2018 | 94 | 0.040 |
Why?
| Germany | 1 | 2018 | 85 | 0.040 |
Why?
| Quantitative Trait Loci | 1 | 2020 | 309 | 0.040 |
Why?
| Drug Therapy, Combination | 1 | 2020 | 955 | 0.040 |
Why?
| Collagen | 1 | 2020 | 416 | 0.040 |
Why?
| Disease Susceptibility | 1 | 2019 | 316 | 0.040 |
Why?
| Anxiety | 1 | 2023 | 845 | 0.040 |
Why?
| Cost-Benefit Analysis | 1 | 2020 | 544 | 0.040 |
Why?
| Diseases in Twins | 1 | 2018 | 175 | 0.040 |
Why?
| Image Processing, Computer-Assisted | 1 | 2021 | 698 | 0.040 |
Why?
| Neoplasm Proteins | 1 | 2020 | 385 | 0.030 |
Why?
| Immunity, Innate | 1 | 2022 | 723 | 0.030 |
Why?
| Twins | 1 | 2018 | 240 | 0.030 |
Why?
| Capillaries | 1 | 2017 | 91 | 0.030 |
Why?
| Immunoglobulin G | 1 | 2021 | 776 | 0.030 |
Why?
| Molecular Sequence Annotation | 1 | 2016 | 81 | 0.030 |
Why?
| Double-Blind Method | 1 | 2020 | 1664 | 0.030 |
Why?
| Metabolomics | 1 | 2021 | 527 | 0.030 |
Why?
| Tertiary Care Centers | 1 | 2016 | 126 | 0.030 |
Why?
| Organ Specificity | 1 | 2016 | 270 | 0.030 |
Why?
| Fetal Blood | 1 | 2016 | 270 | 0.030 |
Why?
| Thyroid Gland | 1 | 2015 | 83 | 0.030 |
Why?
| North America | 1 | 2015 | 259 | 0.030 |
Why?
| Overweight | 1 | 2018 | 474 | 0.030 |
Why?
| Health Services Accessibility | 1 | 2020 | 765 | 0.030 |
Why?
| Patient Preference | 1 | 2015 | 169 | 0.030 |
Why?
| T-Lymphocytes | 1 | 2021 | 1747 | 0.030 |
Why?
| Research Design | 1 | 2019 | 930 | 0.030 |
Why?
| Hospitals, Pediatric | 1 | 2016 | 477 | 0.030 |
Why?
| Models, Biological | 1 | 2019 | 1636 | 0.030 |
Why?
| Genome | 1 | 2014 | 271 | 0.030 |
Why?
| DNA Mutational Analysis | 1 | 2013 | 372 | 0.030 |
Why?
| Ubiquitins | 1 | 2011 | 31 | 0.020 |
Why?
| Epigenesis, Genetic | 1 | 2016 | 524 | 0.020 |
Why?
| Patient Acceptance of Health Care | 1 | 2017 | 679 | 0.020 |
Why?
| DNA Replication | 1 | 2011 | 202 | 0.020 |
Why?
| Genetic Loci | 1 | 2011 | 264 | 0.020 |
Why?
| Treatment Outcome | 2 | 2016 | 9122 | 0.020 |
Why?
| Histocompatibility Testing | 1 | 2010 | 116 | 0.020 |
Why?
| Body Composition | 1 | 2013 | 586 | 0.020 |
Why?
| Telomere | 1 | 2011 | 202 | 0.020 |
Why?
| Cytokines | 1 | 2017 | 1843 | 0.020 |
Why?
| HLA-A Antigens | 1 | 2009 | 50 | 0.020 |
Why?
| HLA-B Antigens | 1 | 2009 | 56 | 0.020 |
Why?
| Hyperinsulinism | 1 | 2010 | 103 | 0.020 |
Why?
| Chromosomes, Human, Pair 5 | 1 | 2008 | 24 | 0.020 |
Why?
| United States | 2 | 2015 | 12226 | 0.020 |
Why?
| Chromosomes, Human, Pair 3 | 1 | 2008 | 49 | 0.020 |
Why?
| Interferon-Induced Helicase, IFIH1 | 1 | 2008 | 14 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2016 | 2551 | 0.020 |
Why?
| Homozygote | 1 | 2009 | 188 | 0.020 |
Why?
| Conserved Sequence | 1 | 2009 | 218 | 0.020 |
Why?
| Heterozygote | 1 | 2009 | 251 | 0.020 |
Why?
| Pedigree | 1 | 2009 | 467 | 0.020 |
Why?
| Base Sequence | 1 | 2011 | 2119 | 0.020 |
Why?
| DNA | 1 | 2014 | 1352 | 0.020 |
Why?
| Tissue Donors | 1 | 2010 | 326 | 0.020 |
Why?
| Genome, Human | 1 | 2009 | 351 | 0.020 |
Why?
| Molecular Sequence Data | 1 | 2011 | 2796 | 0.020 |
Why?
| Logistic Models | 1 | 2011 | 1839 | 0.020 |
Why?
| Mice | 1 | 2022 | 14927 | 0.020 |
Why?
| Body Mass Index | 1 | 2013 | 1967 | 0.020 |
Why?
| Registries | 1 | 2013 | 1763 | 0.020 |
Why?
| Gene Expression Profiling | 1 | 2011 | 1523 | 0.020 |
Why?
| Retrospective Studies | 1 | 2016 | 12547 | 0.010 |
Why?
| Aged, 80 and over | 1 | 2010 | 6357 | 0.010 |
Why?
|
|
Steck's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|